Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.79 |
| ▸ | FBP1 | P09467 | 4/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.58 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093662 | 0.94 | EGFR (0.71) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7093470 | 0.93 | EGFR (0.69) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7092754 | 0.90 | EGFR (0.78) | EGFRFBP1ERBB2 | |
| SCHEMBL7093305 | 0.89 | EGFR (1.00) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7093770 | 0.89 | EGFR (0.82) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL6234224 | 0.89 | EGFR (1.00) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7089155 | 0.87 | EGFR (0.79) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7088562 | 0.87 | EGFR (0.79) | EGFRFBP1ERBB2ERBB4 | |
| SCHEMBL7091689 | 0.86 | EGFR (0.78) | EGFRFBP1ERBB2ERBB4 | |
| Bromide SCHEMBL7143199 | 0.86 | EGFR (0.78) | EGFRFBP1ERBB2ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | BAUER PAUL H (US) | 2003-07-31 | — | — | US | claimed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11573224-B2 | Methods of detection using X-ray fluorescence | ICAGEN, LLC (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200278346-A1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ADJACENT ACQUISITION CO., LLC | 2020-09-03 | — | — | US | disclosed |
| US-20150309021-A1 | Advanced Drug Development and Manufacturing | LOS ALAMOS NATIONAL SECURITY, LLC | 2015-10-29 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144308-A1 | Fructose 1,6-bisphosphatase inhibitors | FBP1, HK1, G6PC1 | EGFR 2906/4885FBP1 1/4885ERBB2 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.